Prof. Rob Phillips PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia

Uscom delivers record growth in a rapidly shrinking commercial world. Medical technology is a cornerstone of health and investment, and Uscom continues to execute a targeted global strategy of growth and expansion. While the future is uncertain, China, Uscom’s major market, is rebounding, as Uscom is expanding into Europe and the US. Uscom has life saving devices in all the major global markets and a product pipeline to ensure revenue growth foreseeably. Uscom is becoming a global, vertically integrated Medical Technology leader.

THE USCOM MISSION Ambitious and growth driven Uscom – The Measure of Life RAP©

RESULTS – RECORD YEAR 1. Record annual cash receipts $4.6M (up 36%), revenue and sales 2. Record annual net cash flow up $2.07M and debt free 3. Record H2 – First profitable and cash flow positive half 4. Record H2 – Cash receipts $3.02M (up 84%), Sales $2.87 (up 64%) 5. Record H2 receipts, revenue and sales approx. = full FY19 results 6. Record Q4 – Cash receipts ($1M) 7. Record Q4 – Sales ($0.87M)

➢ Record Cash Receipts and Sales ➢ Growth Trend Continues ➢ Cash Receipts $4.6M up 36% ➢ H2 Profitable ➢ Cash on Hand

restructure, with record H2 Cash Receipts ➢ Cash on hand ➢ Debt free

Sales Revenue Cash Receipts and record cash receipts ➢ Receipts, revenue and cash ➢ Profit up $0.78M ➢ Profitable, cash flow positive flow equa

➢ Net Cash flow up $0.10M ➢ Cash on hand up 57% Sales Revenue Cash Receipts

INNOVATION Uscom technology provides the highest quality personal spirometers allowing home lung function testing at research standards. Uscom Digital Spirometry U l t r a s o n i c F l o w Te c h n o l o g y “FOR MEDICAL TECHNOLOGY COMPANIES INNOVATION DETERMINES FUTURE REVENUE USCOM CONTINUES TO DEVELOP NEW DEVICES AND IMPROVES CURRENT

VentiTest is a multi-path ultrasonic ventilator test device with PC based display and analytics designed for pressure, flow and volume testing and calibration of ventilator outputs. Uscom is increasing manufacture and marketing of VENTITEST Hospital Departments need 1 VentiTest per 10 ventilators, Estimated 10,000 unit sales = $25M revenue ✓ Unique Technology Based on multi-path digital ultrasound ✓ High Market Interest Exploding demand for COVID-19 ventilators worldwide Around 1M ventilators all require regular calibration

GROWING GLOBAL • Operations Sydney Beijing Budapest Offices Singapore Auckland London LA • Multiple products hedged for currencies and markets

VENTITEST – Uscom ventilator calibration BP+ and SpiroSonic approvals due for China and US Europe and US up-grading and increasing infectious disease centres New European and US distribution models Uscom China growing - numbers and quality of distributors China economy rebounding – boom marke

Regulatory approvals become trade protection Global disorder and slow economic recovery Travel limitation impairs global management Compliance overload – cost, intervention and inefficiency

UCM – TIGHTLY HELD Quality growth stock Invested management Strong strategic vision Record growth in fundamentals Investor 1 Investor 2a Investor 2b Investor 3 ~150M FPO UCM shares on issue ~35±10c (Current price 22c) ~$35M Cap Value Top 20 own 68% CEO and NED own ~20% each China Director and Distributor owns ~1.5% each UCM is tightly held by experienced investors Distributor Investor 4 China Director Investor 5 11 to 20 Free Float

Record Cash Receipts China Strong and Rebounding Europe Expanding $4.6M up 36% with cash on hand Expanding operations and recovering activity and orders China strong and rebounding cash flow positive, debt free sales activity increasing for market in second half

2020 was a year of record financial results with profit and cash flow positivity and rapid growth in the second half following global restructure and Uscom China establishment. Investment in China and all major markets is planned to deliver continuing growth with new products to drive future revenues. Uscom is establishing a company of global clinical, social and commercial importance and significant investor value. Prof. Rob Phillips CEO

Prof. Rob Phillips PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia

Corporate Social Responsibility Winning the battle against Cape York’s feral pigs